Published in Eur Respir J on June 07, 2010
An Open Multiple Dose Titration Study In Patients With Pulmonary Hypertension | NCT00454558
Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation (2011) 2.48
Dietary nitrate ameliorates pulmonary hypertension: cytoprotective role for endothelial nitric oxide synthase and xanthine oxidoreductase. Circulation (2012) 1.94
Reactive oxygen and nitrogen species in pulmonary hypertension. Free Radic Biol Med (2012) 1.19
Pulmonary arterial hypertension. Orphanet J Rare Dis (2013) 1.18
Advances in pediatric pulmonary arterial hypertension. Curr Opin Cardiol (2012) 1.18
Nitric oxide synthases in heart failure. Antioxid Redox Signal (2012) 1.07
Nitric oxide deficiency in pulmonary hypertension: Pathobiology and implications for therapy. Pulm Circ (2013) 1.05
Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats. PLoS One (2011) 1.04
The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats. PLoS One (2012) 1.00
Signal transduction in the development of pulmonary arterial hypertension. Pulm Circ (2013) 0.95
Treating pulmonary arterial hypertension: current treatments and future prospects. Ther Adv Chronic Dis (2011) 0.93
Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension. Pulm Circ (2013) 0.90
Overview of current therapeutic approaches for pulmonary hypertension. Pulm Circ (2011) 0.89
Stimulators and activators of soluble guanylate cyclase: review and potential therapeutic indications. Crit Care Res Pract (2012) 0.87
New perspectives for the treatment of pulmonary hypertension. Br J Pharmacol (2011) 0.87
Exercise training improves exercise capacity and quality of life in patients with inoperable or residual chronic thromboembolic pulmonary hypertension. PLoS One (2012) 0.87
Pulmonary hypertension 2015: current definitions, terminology, and novel treatment options. Clin Res Cardiol (2014) 0.86
cGMP becomes a drug target. Naunyn Schmiedebergs Arch Pharmacol (2012) 0.85
Motivations of patients with pulmonary arterial hypertension to participate in randomized clinical trials. Clin Trials (2012) 0.84
Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Clin Pharmacol Ther (2014) 0.83
The endothelial ADMA/NO pathway in hypoxia-related chronic respiratory diseases. Biomed Res Int (2014) 0.81
Absorption of riociguat (BAY 63-2521): bioavailability, food effects, and dose proportionality. Pulm Circ (2016) 0.80
Novel Therapeutic Strategies for Reducing Right Heart Failure Associated Mortality in Fibrotic Lung Diseases. Biomed Res Int (2015) 0.78
Chronic thromboembolic pulmonary hypertension: Medical treatment. Pulm Circ (2013) 0.78
Progress in the diagnosis and management of pulmonary hypertension in children. Curr Opin Pediatr (2014) 0.78
Mechanics and mechanisms of pulmonary hypertension-Conference summary and translational perspectives. Pulm Circ (2013) 0.77
Targeting soluble guanylate cyclase for the treatment of pulmonary hypertension. Expert Rev Respir Med (2011) 0.77
Assessment of the effects of hepatic impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521). Pulm Circ (2016) 0.76
Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. P T (2014) 0.76
Stimulators of soluble guanylyl cyclase: future clinical indications. Ochsner J (2013) 0.75
Pulmonary hypertension-"state of the art" management in 2012. Indian Heart J (2012) 0.75
Pharmacologic treatments for pulmonary hypertension: exploring pharmacogenomics. Future Cardiol (2013) 0.75
Riociguat (BAY 63-2521) and aspirin: a randomized, pharmacodynamic, and pharmacokinetic interaction study. Pulm Circ (2016) 0.75
Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary disease. Pulm Circ (2015) 0.75
Assessment of the effects of renal impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521). Pulm Circ (2016) 0.75
Treatment of patients with chronic thrombo embolic pulmonary hypertension: focus on riociguat. Ther Clin Risk Manag (2016) 0.75
Riociguat: Something new in pulmonary hypertension therapeutics? J Pharmacol Pharmacother (2015) 0.75
Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension. Drug Des Devel Ther (2017) 0.75
Medical therapies for pulmonary arterial hypertension. Heart Fail Rev (2016) 0.75
Real-time quantitative RT-PCR after laser-assisted cell picking. Nat Med (1998) 7.34
Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J (2009) 6.64
[German guideline for diagnosis and management of idiopathic pulmonary fibrosis]. Pneumologie (2013) 3.03
Sildenafil treatment for portopulmonary hypertension. Eur Respir J (2006) 2.58
Enhanced release of superoxide from polymorphonuclear neutrophils in obstructive sleep apnea. Impact of continuous positive airway pressure therapy. Am J Respir Crit Care Med (2000) 2.55
Reproduction of transfusion-related acute lung injury in an ex vivo lung model. Blood (1990) 2.54
Impaired cardiac autonomic control relates to disease severity in pulmonary hypertension. Eur Respir J (2009) 2.31
First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J (2009) 2.04
Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med (2000) 1.95
Cytochrome c oxidase: structure and spectroscopy. Annu Rev Biophys Biomol Struct (1998) 1.92
Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med (1996) 1.87
Extracorporeal membrane oxygenation in nonintubated patients as bridge to lung transplantation. Am J Transplant (2010) 1.87
Monocytes recruited into the alveolar air space of mice show a monocytic phenotype but upregulate CD14. Am J Physiol Lung Cell Mol Physiol (2001) 1.85
Elevated levels of interleukin-8 and transforming growth factor-beta in bronchoalveolar lavage fluid from patients with bronchiolitis obliterans syndrome: proinflammatory role of bronchial epithelial cells. Munich Lung Transplant Group. Transplantation (2000) 1.84
Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J (2006) 1.84
Surfactant alterations in severe pneumonia, acute respiratory distress syndrome, and cardiogenic lung edema. Am J Respir Crit Care Med (1996) 1.79
Reference values for cardiopulmonary exercise testing in healthy volunteers: the SHIP study. Eur Respir J (2008) 1.78
Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J (2008) 1.77
Experience with inhaled iloprost and bosentan in portopulmonary hypertension. Eur Respir J (2007) 1.75
Aerosolised prostacyclin in adult respiratory distress syndrome. Lancet (1993) 1.74
Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J Clin Oncol (1998) 1.72
Cell size of alveolar macrophages: an interspecies comparison. Environ Health Perspect (1997) 1.71
Association of airflow limitation with trauma exposure and post-traumatic stress disorder. Eur Respir J (2010) 1.67
Assessment of the vasodilator response in primary pulmonary hypertension. Comparing prostacyclin and iloprost administered by either infusion or inhalation. Eur Heart J (2003) 1.65
High diagnostic accuracy of NT-proBNP for cardiac origin of pleural effusions. Eur Respir J (2006) 1.64
Late-acute renal allograft rejection and symptomless cytomegalovirus infection. Lancet (1995) 1.63
Inhibition of phosphodiesterase 4 enhances lung alveolarisation in neonatal mice exposed to hyperoxia. Eur Respir J (2008) 1.62
Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J (2008) 1.58
Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group. Ann Intern Med (2000) 1.57
Study of the mass and spin-parity of the Higgs boson candidate via its decays to Z boson pairs. Phys Rev Lett (2013) 1.56
Phenotypic characterization of alveolar monocyte recruitment in acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol (2000) 1.54
Usefulness of exhaled nitric oxide to guide risk stratification for bronchiolitis obliterans syndrome after lung transplantation. Am J Transplant (2010) 1.52
Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest (2001) 1.49
[Sildenafil for treatment of severe pulmonary hypertension and commencing right-heart failure]. Pneumologie (2002) 1.48
Effect of surgical lung volume reduction on respiratory muscle function in pulmonary emphysema. Eur Respir J (1996) 1.48
Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats. Eur Respir J (2010) 1.47
Extracorporeal shock wave treatment raises blood pressure in borderline hypertensive rats. J Urol (1995) 1.45
Long-term outcome with intravenous iloprost in pulmonary arterial hypertension. Eur Respir J (2009) 1.44
Biosynthesis of constitutive nitric oxide synthase-derived nitric oxide attenuates coronary vasoconstriction and myocardial depression in a model of septic heart failure induced by Staphylococcus aureus alpha-toxin. Crit Care Med (2001) 1.43
Fenfluramine blocks low-Mg2+-induced epileptiform activity in rat entorhinal cortex. Epilepsia (2000) 1.42
Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med (1996) 1.42
Toe ulceration associated with compression bandaging: observational study. BMJ (2001) 1.41
Aetiology, diagnosis and management of spontaneous perirenal haematomas. Eur Urol (1996) 1.39
IL-6 independent monocyte/B cell defect in renal transplant recipients with long-term stable graft function. Transplantation (1994) 1.39
The effect of repeated ozone exposures on inflammatory markers in bronchoalveolar lavage fluid and mucosal biopsies. Am J Respir Crit Care Med (2000) 1.36
Bronchoalveolar and systemic cytokine profiles in patients with ARDS, severe pneumonia and cardiogenic pulmonary oedema. Eur Respir J (1996) 1.35
Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact on biophysical and biochemical surfactant properties. Eur Respir J (2002) 1.35
Enhanced tissue factor pathway activity and fibrin turnover in the alveolar compartment of patients with interstitial lung disease. Thromb Haemost (2000) 1.33
Treatment of advanced emphysema with emphysematous lung sealant (AeriSeal®). Respiration (2011) 1.33
Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J (2007) 1.32
Monocyte migration through the alveolar epithelial barrier: adhesion molecule mechanisms and impact of chemokines. J Immunol (2000) 1.32
The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. Eur Respir J (2011) 1.28
Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact on gas exchange and haemodynamics. Eur Respir J (2002) 1.27
Decreased plasma levels of nitric oxide derivatives in obstructive sleep apnoea: response to CPAP therapy. Thorax (2000) 1.27
Direct evidence for a tyrosine radical in the reaction of cytochrome c oxidase with hydrogen peroxide. Biochemistry (1999) 1.26
Regulation of hypoxic pulmonary vasoconstriction: basic mechanisms. Eur Respir J (2008) 1.24
Measurement of the electron charge asymmetry in inclusive W production in pp collisions at sqrt[s]=7 TeV. Phys Rev Lett (2012) 1.23
Surfactant alteration and replacement in acute respiratory distress syndrome. Respir Res (2001) 1.23
Hypoxic vasoconstriction in intact lungs: a role for NADPH oxidase-derived H(2)O(2)? Am J Physiol Lung Cell Mol Physiol (2000) 1.22
Search for new physics in the multijet and missing transverse momentum final state in proton-proton collisions at √s = 7 TeV. Phys Rev Lett (2012) 1.19
Azimuthal anisotropy of charged particles at high transverse momenta in Pb-Pb collisions at sqrt[s(NN)] = 2.76 TeV. Phys Rev Lett (2012) 1.19
The listerial exotoxins listeriolysin and phosphatidylinositol-specific phospholipase C synergize to elicit endothelial cell phosphoinositide metabolism. J Immunol (1996) 1.17
Human endothelial cell activation and mediator release in response to Listeria monocytogenes virulence factors. Infect Immun (2001) 1.16
Pulmonary function and health-related quality of life in a sample of long-term survivors of the acute respiratory distress syndrome. Intensive Care Med (2000) 1.16
Entorhinal cortex entrains epileptiform activity in CA1 in pilocarpine-treated rats. Neurobiol Dis (2005) 1.16
Bridge to thoracic organ transplantation in patients with pulmonary arterial hypertension using a pumpless lung assist device. Am J Transplant (2009) 1.15
Presynaptic nicotine receptors mediating a positive feed-back on transmitter release from the rat phrenic nerve. Naunyn Schmiedebergs Arch Pharmacol (1986) 1.14
Multidisciplinary interobserver agreement in the diagnosis of idiopathic pulmonary fibrosis. Eur Respir J (2007) 1.13
Alteration of fatty acid profiles in different pulmonary surfactant phospholipids in acute respiratory distress syndrome and severe pneumonia. Am J Respir Crit Care Med (2001) 1.13
Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med (1999) 1.13
Endotoxin-induced myocardial tumor necrosis factor-alpha synthesis depresses contractility of isolated rat hearts: evidence for a role of sphingosine and cyclooxygenase-2-derived thromboxane production. Circulation (2000) 1.12
Localized pulmonary infection associated with Mycobacterium tilburgii in an HIV-infected patient. Infection (2005) 1.12
Search for a W' or techni-ρ decaying into WZ in pp Collisions at sqrt[s] = 7 TeV. Phys Rev Lett (2012) 1.10
Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF. Oncogene (2012) 1.09
Search for new physics with same-sign isolated dilepton events with jets and missing transverse energy. Phys Rev Lett (2012) 1.09
Listeriolysin is a potent inducer of the phosphatidylinositol response and lipid mediator generation in human endothelial cells. Infect Immun (1996) 1.09
Low frequency of BMPR2 mutations in a German cohort of patients with sporadic idiopathic pulmonary arterial hypertension. J Med Genet (2004) 1.08
Phosphodiesterase inhibitors for the treatment of pulmonary hypertension. Eur Respir J (2008) 1.08
[Tuberculosis in asylum seekers]. Gesundheitswesen (1995) 1.07
Effects of inhaled versus intravenous vasodilators in experimental pulmonary hypertension. Eur Respir J (1997) 1.06
Inflammation, immunological reaction and role of infection in pulmonary hypertension. Clin Microbiol Infect (2011) 1.06
Combination therapy for pulmonary arterial hypertension: still more questions than answers. Eur Respir J (2004) 1.06
[Multimorbidity and successful aging: the population-based KORA-Age study]. Z Gerontol Geriatr (2011) 1.05
Involvement of glutamic acid 278 in the redox reaction of the cytochrome c oxidase from Paracoccus denitrificans investigated by FTIR spectroscopy. Biochemistry (1998) 1.05
Measurement of the Υ1S, Υ2S, and Υ3S polarizations in pp collisions at sqrt[s] = 7 TeV. Phys Rev Lett (2013) 1.05
Cyclooxygenase isoenzyme localization and mRNA expression in rat lungs. Am J Respir Cell Mol Biol (1998) 1.04
Alveolar surfactant and adult respiratory distress syndrome. Pathogenetic role and therapeutic prospects. Clin Investig (1993) 1.04
Ureterosigmoidostomy: long-term results, risk of carcinoma and etiological factors for carcinogenesis. J Urol (1990) 1.04
Role of Listeria monocytogenes exotoxins listeriolysin and phosphatidylinositol-specific phospholipase C in activation of human neutrophils. Infect Immun (1999) 1.03
Measurement of pulmonary parenchymal attenuation: use of spirometric gating with quantitative CT. Radiology (1990) 1.03
Homocysteine and peripheral arterial disease: systematic review and meta-analysis. Eur J Vasc Endovasc Surg (2009) 1.03
Quantitative PCR analysis of cytokine transcription patterns in peripheral mononuclear cells after anti-CD3 rejection therapy using two novel multispecific competitor fragments. Transplantation (1994) 1.02
Bosentan therapy for portopulmonary hypertension. Eur Respir J (2005) 1.02
Glutamate-cysteine ligase modulatory subunit in BAL alveolar macrophages of healthy smokers. Eur Respir J (2003) 1.02